Sep 14, 2023 / 03:45PM GMT
Travis Lee Steed - BofA Securities, Research Division - MD
I'm Travis Steed, the U.S. medical device analyst at Bank of America. And the last session of the day, where -- save the best for last, we've got ResMed here. Rob Douglas, President and Chief Operating Officer; and Amy Wakeham, head of Investor Relations. Thanks for joining. I think Rob I was going to hand it over to you to make a few opening remarks and if you will, and we can jump into some Q&A.
Robert A. Douglas - ResMed Inc. - President & COO
Sure. Thanks, Travis. Just briefly, if you don't know ResMed, we're best known for treating sleep apnea, but we actually do a lot more than that and we've got really good software businesses, and we're very focused on our COPD treatments as well. As I said, the bulk of our business is treating obstructive sleep apnea, and we're way ahead the market leader in that. And it's a very good market for us. we think the total addressable market is probably close to 1 billion people. It's a very common condition, and we've seen prevalence increasing over the years
Resmed Inc at Bank of America Merrill Lynch Global Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot